Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

By Maetzel A.  

PharmacoEconomics, Vol. 21, Iss. 7, 2003-01 ,pp. : 501-512

Adis International

Access to resources Recommend Favorite

Orlistat weighs in against size of diabetes patients and costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 495, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

By Derosa Giuseppe   Maffioli Pamela   Salvadeo Sibilla AT   Ferrari Ilaria   Gravina Alessia   Mereu Roberto   D'Angelo Angela   Fogari Elena   Palumbo Ilaria   Randazzo Sabrina   Cicero Arrigo FG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 12, 2010-08 ,pp. : 1971-1982

Informa Healthcare

Access to resources Recommend Favorite

The Cost Effectiveness of Orlistat in a 1-Year Weight-Management Programme for Treating Overweight and Obese Patients in Sweden: A Treatment Responder Approach

By Hertzman Peter  

PharmacoEconomics, Vol. 23, Iss. 10, 2005-01 ,pp. : 1007-1020

Adis International

Access to resources Recommend Favorite

Candesartan cilexetil may prevent diabetes in patients with HF

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite